Vanda Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- $311.8M
- Introduction
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
- Conditions
- Non-24-Hour Sleep-Wake Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 136
- Registration Number
- NCT01163032
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸SDS Clinical Trials Inc., Orange, California, United States
🇺🇸St. Johns Sleep Disorder Center - St. Johns Medical Plaza, Santa Monica, California, United States
VEC-162 Study in Adult Patients With Primary Insomnia
- Conditions
- Primary Insomnia
- Interventions
- Drug: VEC-162 20 mgDrug: VEC-162 50 mgDrug: Placebo
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 322
- Registration Number
- NCT00548340
- Locations
- 🇺🇸
Vanda Investigational Site, Dallas, Texas, United States
Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers
- Conditions
- Circadian Rhythm Sleep Disorders
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT00490945
- Locations
- 🇺🇸
Vanda Investigational Site, Detroit, Michigan, United States
VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
- Conditions
- Excessive Somnolence
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2007-11-02
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00467441
- Locations
- 🇫🇷
Vanda Investigational Site, Dijon, France
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
- Conditions
- Insomnia
- Interventions
- Drug: PlaceboDrug: 20 mg VEC-162Drug: 100 mg VEC-162Drug: 50 mg VEC-162
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 411
- Registration Number
- NCT00291187
- Locations
- 🇺🇸
Vanda Investigational Site, Plano, Texas, United States
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 593
- Registration Number
- NCT00254202
- Locations
- 🇮🇳
Vanda Investigational Site, Chinawaltair, Visakha Patnam, India
🇮🇳Vanda Investgational Site, Chennai, Tamilnadu, India